Postmastectomy radiation therapy in breast cancer patients with micrometastatic disease in sentinel node dissection:...

Area of Science:

• Oncology
• Radiation Oncology
• Surgical Oncology

Background:

• The role of postmastectomy radiation therapy (PMRT) in early-stage breast cancer (T1-2) with micrometastatic disease in sentinel lymph node dissection (SLND) remains unclear.
• Establishing the prognostic value of PMRT in this specific patient subgroup is crucial for treatment optimization.

Purpose of the Study:

• To investigate the impact of PMRT on survival outcomes in patients diagnosed with T1-2 breast cancer and micrometastatic disease in SLND.
• To evaluate the efficacy of PMRT in improving breast cancer-specific and overall survival in this population.

Main Methods:

• A register- and population-based cohort study utilizing the BcBase 3.0 database.
• Multivariate Cox regression models were employed to analyze survival data.
• A systematic literature review and meta-analysis were conducted to synthesize existing evidence.

Main Results:

• Analysis of 956 patients revealed no statistically significant difference in breast cancer-specific or overall survival between patients who received PMRT (25%) and those who did not (75%).
• Pooled meta-analysis results from 5-6 studies also indicated that PMRT did not improve breast cancer-specific or overall survival.
• The certainty of evidence for these findings was rated as low, with minimal heterogeneity observed (I² ≤ 10%).

Conclusions:

• Postmastectomy radiation therapy (PMRT) does not appear to influence survival in T1-2 breast cancer patients with micrometastatic disease in SLND.
• Caution is advised when interpreting these results into clinical practice due to the low level of evidence and relatively short follow-up periods in the included studies.